$OLPX
OLAPLEX HOLDINGS, INC. Stock $olpx

$olpx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000186872624000048 Filed on August 06, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$119.1M	$103.9M
YoY Change	-3.62%	-4.85%
Cost Of Revenue	$37.35M	$31.51M
YoY Change	-6.65%	-0.75%
Gross Profit	$81.73M	$72.44M
YoY Change	-2.17%	-6.53%
Gross Profit Margin	68.64%	69.69%
Selling, General & Admin	$42.96M	$45.42M
YoY Change	17.9%	-6.18%
% of Gross Profit	52.56%	62.71%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$13.46M	$13.17M
YoY Change	3.51%	27.6%
% of Gross Profit	16.46%	18.19%
Operating Expenses	$53.74M	$56.16M
YoY Change	14.8%	-4.39%
Operating Profit	$28.00M	$16.28M
YoY Change	-23.79%	-13.23%
Interest Expense	-$9.005M	-$8.335M
YoY Change	-194.69%	-18.33%
% of Operating Profit	-32.17%	-51.2%
Other Income/Expense, Net	$670.0K	-$264.0K
YoY Change	-169.07%	-56.0%
Pretax Income	$19.66M	$7.679M
YoY Change	-25.12%	-3.45%
Income Tax	$4.864M	$1.900M
% Of Pretax Income	24.74%	24.74%
Net Earnings	$14.80M	$5.779M
YoY Change	-27.34%	-6.12%
Net Earnings / Revenue	12.43%	5.56%
Basic Earnings Per Share	$0.02	$0.01
Diluted Earnings Per Share	$0.02	$0.01
COMMON SHARES
Basic Shares Outstanding	662.0M shares	661.8M shares
Diluted Shares Outstanding	666.2M shares	663.5M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$538.8M	$507.9M
YoY Change	25.43%	34.22%
Cash & Equivalents	$538.8M	$507.9M
Short-Term Investments
Other Short-Term Assets	$10.09M	$12.39M
YoY Change	57.21%	-7.5%
Inventory	$85.91M	$100.2M
Prepaid Expenses
Receivables	$34.89M	$33.98M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$669.7M	$654.5M
YoY Change	11.5%	14.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.238M	$1.225M
YoY Change	33.26%	31.44%
Goodwill	$168.3M	$168.3M
YoY Change	0.0%	0.0%
Intangibles	$911.5M	$923.4M
YoY Change	-5.04%	-4.97%
Long-Term Investments	$8.430M	$9.365M
YoY Change
Other Assets	$8.430M	$9.365M
YoY Change	-32.24%	-17.52%
Total Long-Term Assets	$1.089B	$1.102B
YoY Change	-4.56%	-4.34%
TOTAL ASSETS
Total Short-Term Assets	$669.7M	$654.5M
Total Long-Term Assets	$1.089B	$1.102B
Total Assets	$1.759B	$1.757B
YoY Change	0.98%	1.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.36M	$23.02M
YoY Change	-14.93%	68.45%
Accrued Expenses	$19.80M	$22.51M
YoY Change	13.72%	-8.7%
Deferred Revenue	$1.130M	$1.125M
YoY Change	-8.5%	-45.84%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.750M	$6.750M
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$56.56M	$70.62M
YoY Change	0.65%	15.3%
LONG-TERM LIABILITIES
Long-Term Debt	$645.0M	$646.4M
YoY Change	-0.82%	-0.81%
Other Long-Term Liabilities	$1.798M	$1.932M
YoY Change	1.7%	-98.98%
Total Long-Term Liabilities	$646.8M	$648.3M
YoY Change	-0.81%	-22.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$56.56M	$70.62M
Total Long-Term Liabilities	$646.8M	$648.3M
Total Liabilities	$879.4M	$893.4M
YoY Change	-2.48%	-1.28%
SHAREHOLDERS EQUITY
Retained Earnings	$554.8M	$540.0M
YoY Change	8.28%	9.75%
Common Stock	$662.0K	$676.0K
YoY Change	1.22%	3.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$879.7M	$863.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.759B	$1.757B
YoY Change	0.98%	1.96%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$14.80M	$5.779M
YoY Change	-27.34%	-6.12%
Depreciation, Depletion And Amortization	$13.46M	$13.17M
YoY Change	3.51%	27.6%
Cash From Operating Activities	$33.46M	$16.24M
YoY Change	-37.34%	-39.84%
INVESTING ACTIVITIES
Capital Expenditures	$1.191M	$1.094M
YoY Change	32.33%	-19.85%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.191M	-$1.094M
YoY Change	32.33%	-19.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.366M	-14.73M
YoY Change	5.08%	-11.03%
NET CHANGE
Cash From Operating Activities	33.46M	16.24M
Cash From Investing Activities	-1.191M	-1.094M
Cash From Financing Activities	-1.366M	-14.73M
Net Change In Cash	30.90M	419.0K
YoY Change	-39.64%	-95.38%
FREE CASH FLOW
Cash From Operating Activities	$33.46M	$16.24M
Capital Expenditures	$1.191M	$1.094M
Free Cash Flow	$32.27M	$15.15M
YoY Change	-38.53%	-40.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-630000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6632000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	4616000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15797000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1845000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-331000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	59949000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	559000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	1619000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2178000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	225000	usd
	olpx	Payment To Pre Ipo Stockholders Pursuant To Tax Receivable Agreement PaymentToPreIPOStockholdersPursuantToTaxReceivableAgreement	12613000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	3375000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-17481000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	55610000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	322808000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	507925000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	378418000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	9511000	usd
	us-gaap	Interest Paid Net InterestPaidNet	29344000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	6156000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10657000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	4627000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3918000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	175000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	780957000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	20964000	usd
CY2023Q1	olpx	Stock Issued During Period Value Non Option Equity Instruments Exercised StockIssuedDuringPeriodValueNonOptionEquityInstrumentsExercised	326000	usd
CY2023Q1	olpx	Share Based Payment Arrangement Shares Withheld For Tax Withholding Obligation Amount ShareBasedPaymentArrangementSharesWithheldForTaxWithholdingObligationAmount	390000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3299000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2018000	usd
CY2023Q1	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1	-557000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	806617000	usd
	us-gaap	Net Income Loss NetIncomeLoss	13525000	usd
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	4489000	usd
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	3706000	usd
	olpx	Amortization Of Other Intangible Assets AmortizationOfOtherIntangibleAssets	22025000	usd
	olpx	Amortization Of Other Intangible Assets AmortizationOfOtherIntangibleAssets	20647000	usd
	olpx	Inventory Write Down And Disposal InventoryWriteDownAndDisposal	2516000	usd
	olpx	Inventory Write Down And Disposal InventoryWriteDownAndDisposal	6167000	usd
	us-gaap	Depreciation Depreciation	284000	usd
	us-gaap	Depreciation Depreciation	230000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	906000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	906000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-450000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1240000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6044000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4652000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-530000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6945000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4078000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4047000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	28000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	75087000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	128000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	500000	usd
	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	1368000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1996000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4097000	usd
	olpx	Payment To Pre Ipo Stockholders Pursuant To Tax Receivable Agreement PaymentToPreIPOStockholdersPursuantToTaxReceivableAgreement	16452000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	5062000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-16246000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	41525000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466400000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	10554000	usd
	us-gaap	Interest Paid Net InterestPaidNet	25008000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	742000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	olpx	Transfer To Due To Related Parties TransferToDueToRelatedParties	571000	usd
	olpx	Transfer To Due To Related Parties TransferToDueToRelatedParties	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	21000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Examples of estimates and assumptions include: for revenue recognition, determining the nature and timing of satisfaction of performance obligations, variable consideration, and other obligations such as product returns, allowance for promotions, and refunds; loss contingencies; the fair value of share-based options and stock settled stock appreciation rights (“SARs”); the fair value of and/or potential impairment of goodwill and intangible assets for the Company’s reporting unit; the fair value of the Company’s Interest Rate Caps (as defined below in “Note 5 - Fair Value Measurement”); useful lives of the Company’s tangible and intangible assets; estimated income tax expense and tax payments; future payment obligations under the Tax Receivable Agreement; and the net realizable value of, and demand for the Company’s inventory. Actual results and outcomes may differ from management’s estimates and assumptions due to risks and uncertainties.</span></div>
CY2021Q4	olpx	Tax Receivable Agreement Percent Of Tax Benefits With Provided Payment TaxReceivableAgreementPercentOfTaxBenefitsWithProvidedPayment	0.85
CY2021Q4	olpx	Tax Receivable Agreement Percent Of Tax Benefits Retained By Company TaxReceivableAgreementPercentOfTaxBenefitsRetainedByCompany	0.15
CY2024Q2	olpx	Tax Receivable Agreement TaxReceivableAgreement	185400000	usd
	olpx	Related Party Transaction Term Of Agreement RelatedPartyTransactionTermOfAgreement	P11Y
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts presented have been reclassified within the “Condensed Consolidated Statements of Operations and Comprehensive Income” to conform with the current period presentation, including a prior year reclassification from Interest expense, net to Interest income for the three and six months ended June 30, 2023. The reclassifications occurred as a result of an increase in the significance of the current year amount. There was no change to the Condensed Consolidated Balance Sheet, Statements of Operations and Comprehensive Income, and Statements of Cash Flows from the reclassification.</span></div>
CY2024Q2	olpx	Number Of Business Channels NumberOfBusinessChannels	3	business_channel
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103943000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	109241000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	202849000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	223028000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103943000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	109241000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	202849000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	223028000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	25922000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	30306000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	74234000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	65616000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	100156000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	95922000	usd
CY2024Q2	us-gaap	Inventory Write Down InventoryWriteDown	1600000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	2500000	usd
CY2023Q2	us-gaap	Inventory Write Down InventoryWriteDown	3600000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	6200000	usd
CY2023	olpx	Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag	2022 Interest Rate Cap at December 31, 2023
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1149447000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	226021000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	923426000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	168300000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	168300000	usd
CY2024Q2	olpx	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	1317747000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	226021000	usd
CY2024Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1091726000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1147160000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	199446000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	947714000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	168300000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	168300000	usd
CY2023Q4	olpx	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	1315460000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	199446000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1116014000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2302000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1964000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4489000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3706000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4590000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4133000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4835000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4639000	usd
CY2024Q2	olpx	Accrued Freight Current AccruedFreightCurrent	2497000	usd
CY2023Q4	olpx	Accrued Freight Current AccruedFreightCurrent	1229000	usd
CY2024Q2	us-gaap	Accrued Advertising Current And Noncurrent AccruedAdvertisingCurrentAndNoncurrent	5620000	usd
CY2023Q4	us-gaap	Accrued Advertising Current And Noncurrent AccruedAdvertisingCurrentAndNoncurrent	6348000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1125000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1051000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	419000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	431000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3419000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2745000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22505000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20576000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	6695000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	7415000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	653117000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	655773000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	6750000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	6750000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	646367000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	649023000	usd
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	8300000	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	10200000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	16600000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	20700000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	653100000	usd
CY2024Q2	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	633400000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	655800000	usd
CY2023Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	615100000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4413328	shares
CY2024Q2	olpx	Payments For Tax Receivable Agreement PaymentsForTaxReceivableAgreement	12600000	usd
	olpx	Payments For Tax Receivable Agreement PaymentsForTaxReceivableAgreement	12600000	usd
CY2023Q2	olpx	Payments For Tax Receivable Agreement PaymentsForTaxReceivableAgreement	16600000	usd
	olpx	Payments For Tax Receivable Agreement PaymentsForTaxReceivableAgreement	16600000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	CONTINGENCIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to various legal actions arising in the ordinary course of business. The Company cannot predict with reasonable assurance the outcome of these legal actions brought against the Company as they are subject to uncertainties. Accordingly, any settlement or resolution in these legal actions may occur and affect the Company’s net income in such period as the settlement or resolution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pending Legal Proceedings: </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, a putative securities class action was filed against the Company and certain of its current and former officers and directors in the United States District Court for the Central District of California, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lilien v. Olaplex Holdings, Inc. et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-08395. A consolidated complaint was filed on April 28, 2023, which names as additional defendants the underwriters for the Company’s IPO and various stockholders that sold shares of common stock of the Company in the IPO. The action is brought on behalf of a putative class of purchasers of the Company’s common stock in or traceable to the Company’s IPO and asserts claims under Sections 11, 12, and 15 of the Securities Act of 1933. The action seeks certification of the putative class, compensatory damages, attorneys’ fees and costs, and any other relief that the court determines is appropriate. The defendants moved to dismiss the consolidated complaint on July 19, 2023. The court held hearings on the defendants’ motions to dismiss on October 16, 2023 and July 1, 2024. A decision has yet to be issued. The underwriter defendants have notified the Company of their intent to seek indemnification from the Company pursuant to the IPO underwriting agreement regarding the claims asserted in this action. The Company intends to vigorously defend the pending lawsuit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2023, a purported derivative action was filed against the Company, Advent International Corporation, and certain of the Company’s current and former officers and directors in the United States District Court for the Central District of California, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ciuffo v. Dagousset, et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., No. 2:23-cv-09712-SVW-SK. This action is premised on allegations similar to those asserted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lilien</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> federal securities litigation. On February 1, 2024, the parties filed a joint stipulation to stay the purported derivative action pending a decision on the motions to dismiss filed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lilien </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal securities action. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2024, a second purported derivative action was filed against the Company, Advent International Corporation, and certain of the Company’s current and former officers and directors in the United States District Court for the Central District of California, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hutchinson v. Advent International Corporation, et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., No. 2:24-cv-02364. This action is premised on allegations similar to those asserted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lilien</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> federal securities litigation and in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ciuffo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> federal derivative action. On April 19, 2024, the parties in both purported derivative actions filed a joint stipulation to consolidate the two derivative actions and to stay proceedings in the consolidated case.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2023, twenty-eight plaintiffs filed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albahae, et al. v. Olaplex Holdings, Inc., et al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No. 2:23-cv-00982, a complaint alleging personal and economic injury and asserting claims for breach of warranty, negligence/gross negligence, products liability, unjust enrichment, and violations of California False Advertising Law and Unfair Competition Law, against the Company and Cosway Company, Inc., the Company’s primary contract manufacturer, in the United States District Court for the Central District of California. On March 2, 2023, the plaintiffs amended the complaint to include seventy-three additional plaintiffs. The plaintiffs allege that certain ingredients used in some Company products have purportedly caused irritation or posed a hazard to consumers, and that the Company engaged in misrepresentation with respect to those products. The plaintiffs seek actual and consequential damages, punitive damages, restitution in the form of disgorgement of profits, attorneys’ fees and costs, and any other relief that the court determines is appropriate. On April 17, 2023, the Company moved to dismiss and to sever the plaintiffs’ claims. On July 11, 2023, the Court granted the Company’s motion to sever and dismissed all but the first named plaintiff. The Court also dismissed the operative complaint with leave to re-file on the grounds that it now contained allegations that were not relevant to the claims of the one, remaining plaintiff. On July 24, 2023, the remaining plaintiff filed a notice, voluntarily dismissing her claims without prejudice. As of the date of issuance of these Condensed Consolidated Financial Statements, none of the plaintiffs have re-filed their claims. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any potential loss associated with these pending legal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceedings</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is not probable or reasonably estimable at this time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024 and December 31, 2023, the Company was not subject to any other currently pending legal matters or claims that could have a material adverse effect on its financial position, results of operations, or cash flows should such litigation be resolved unfavorably.</span></div>
CY2023Q1	us-gaap	Loss Contingency Number Of Plaintiffs LossContingencyNumberOfPlaintiffs	28	plaintiff
CY2023Q1	us-gaap	Loss Contingency Number Of Plaintiffs LossContingencyNumberOfPlaintiffs	73	plaintiff
CY2023Q3	us-gaap	Loss Contingency Number Of Plaintiffs LossContingencyNumberOfPlaintiffs	1	plaintiff
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	5779000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	6156000	usd
	us-gaap	Net Income Loss NetIncomeLoss	13525000	usd
	us-gaap	Net Income Loss NetIncomeLoss	27120000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	661734667	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	654345056	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	661278793	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	653045245	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1810591	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	26004105	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2237906	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	29062487	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	663545258	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	680349161	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	663516699	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	682107732	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10269710	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9578809	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2965541	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1459061	shares
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001868726-24-000048-index-headers.html	Edgar Link	pending
0001868726-24-000048-index.html	Edgar Link	pending
0001868726-24-000048.txt	Edgar Link	pending
0001868726-24-000048-xbrl.zip	Edgar Link	pending
am.jpg	Edgar Link	pending
ex101-kosturosengagementle.htm	Edgar Link	pending
ex311-ceocertificationq220.htm	Edgar Link	pending
ex312-cfocertificateq22024.htm	Edgar Link	pending
ex321-ceocertificateq22024.htm	Edgar Link	pending
ex322-cfocertificateq22024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
olpx-20240630.htm	Edgar Link	pending
olpx-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
olpx-20240630_cal.xml	Edgar Link	unprocessable
olpx-20240630_def.xml	Edgar Link	unprocessable
olpx-20240630_lab.xml	Edgar Link	unprocessable
olpx-20240630_pre.xml	Edgar Link	unprocessable
olpx-20240630_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
screenshot2024-07x12155052.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OLPX
OLAPLEX HOLDINGS, INC. Stock $olpx

2024 Q3 Form 10-Q Financial Statement

#000186872624000048 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OLPX OLAPLEX HOLDINGS, INC. Stock $olpx

2024 Q3 Form 10-Q Financial Statement

#000186872624000048 Filed on August 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OLPX
OLAPLEX HOLDINGS, INC. Stock $olpx